[Translation] A multicenter, randomized, double-blind, parallel-controlled phase III clinical study to evaluate the efficacy and safety of indapamide extended-release tablets of olisartan medoxomil in patients with essential hypertension whose blood pressure cannot be effectively controlled by olisartan medoxomil monotherapy

探索阿利沙坦酯吲达帕胺缓释片在阿利沙坦酯单药治疗4周后不能有效控制血压的原发性高血压患者的有效性和安全性。

[Translation]

To explore the efficacy and safety of indapamide extended-release tablets of olisartan medoxomil in patients with essential hypertension whose blood pressure cannot be effectively controlled after 4 weeks of olisartan medoxomil monotherapy.

Start Date28 Apr 2022

Sponsor / Collaborator

Shenzhen Salubris Pharmaceuticals Co., Ltd.

CTR20220214 / CompletedPhase 1

阿利沙坦酯吲达帕胺缓释片与阿利沙坦酯片、吲达帕胺缓释片联合给药在健康人体内的相对生物利用度研究

[Translation] Study on the relative bioavailability of allisartan medoxomil-indapamide sustained-release tablets and allisartan medoxomil tablets and indapamide sustained-release tablets in healthy volunteers

健康成年受试者分别单次口服阿利沙坦酯吲达帕胺缓释片（240mg/1.5mg）或阿利沙坦酯片（240mg）联合吲达帕胺缓释片（1.5mg），评价二者的相对生物利用度、药代动力学特征、安全性和耐受性。

[Translation]

Healthy adult subjects were given a single oral dose of ollisartan medoxomil-indapamide sustained-release tablets (240 mg/1.5 mg) or ollisartan medoxomil tablets (240 mg) combined with indapamide sustained-release tablets (1.5 mg) to evaluate their relative bioavailability, pharmacokinetic characteristics, safety, and tolerability.

Start Date17 Feb 2022

Sponsor / Collaborator

Shenzhen Salubris Pharmaceuticals Co., Ltd.

NCT06500689 / CompletedPhase 3

Efficacy and Safety of Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil: A Phase III, Multicenter, Randomized, Double-blind, Parallel-controlled, 52-week Clinical Study

The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/sustained-release indapamide (240 mg/1.5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with Allisartan Isoproxil (240 mg).

Start Date30 Dec 2021

Sponsor / Collaborator

Shenzhen Salubris Pharmaceuticals Co., Ltd.

100 Clinical Results associated with Allisartan Isoproxil/Indapamide

100 Translational Medicine associated with Allisartan Isoproxil/Indapamide

100 Patents (Medical) associated with Allisartan Isoproxil/Indapamide

100 Deals associated with Allisartan Isoproxil/Indapamide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Essential Hypertension	NDA/BLA	CN	Shenzhen Salubris Pharmaceuticals Co., Ltd.	12 Sep 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis